LearnGlossaryMarketStocksSuperinvestorsSign in

INVA

Innoviva, Inc.

Healthcare · $1.5B market cap

Verdict

Share price

$20.50

close of Oct 3, 2026

Fair value

$16.75

Sticker Price

Payback Price

$6.70

buy price

Overpriced

INVA is Overpriced: at $20.50 it trades 22% above its fair value of $16.75. Its buy price (Payback Price) is $6.70, 67% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.

How we valued it

Free Cash Flow. Sales grew 9% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth2.4% a year✗
Equity per share growth26.7% a year✓
Sales growth13.6% a year✓
Free cash flow growth4.1% a year✗
Return on invested capital8.5%✗

Follow INVA

Get notified when it reaches its buy price of $6.70. Free.

Create a free account

Insider activity

Since Aug 20, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Raifeld Pavel

Chief Executive Officer · 2026-08-20

Tax withholding

$24K

Basso Stephen

Chief Financial Officer · 2026-08-20

Tax withholding

$12K

Zhen Marianne

Chief Accounting Officer · 2026-08-20

Tax withholding

$24K

About Innoviva, Inc.

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works